Lifestance Health Group, Inc. (LFST)

LifeStance Health Group's stock price has been impacted by several events in the past six months. The stock experienced a significant surge on March 24, 2026, following a high-conviction upgrade from an investment bank, citing the company's operational turnaround, first year of GAAP profitability in 2025, and strong revenue growth potential. Conversely, the stock declined around March 12, 2026, trading below its 50-day moving average amid rising short interest and mixed Q4 2025 results. On February 25, 2026, following its Q4 2025 earnings announcement, LFST shares gained 3.8%. Analyst price targets have seen increases from Barclays, Canaccord, and UBS around late February/early March 2026. Despite positive clinical data released on April 9, 2026, showing significant improvement in anxiety and depression for patients, some analysts continue to note a wide valuation gap, leading to mixed investor sentiment. The stock also saw a modest gain on April 8, 2026, amid a broader market relief rally sparked by a US-Iran ceasefire agreement.

LifeStance Health Group, Inc. has a seasonality score of 4. The nature of mental healthcare demand can sometimes be influenced by academic calendars, holidays, and changes in insurance benefits at the start of a new year. The company's mission to expand access to mental health treatment and its hybrid care model may help to mitigate some seasonal fluctuations by offering flexible options.

LifeStance Health Group, Inc. is a leading provider of outpatient mental healthcare services in the United States, offering both virtual and in-person treatment options. The company is dedicated to improving access to trusted, affordable, and personalized mental healthcare for children, adolescents, and adults experiencing a variety of mental health conditions. The company's patient-focused platform integrates clinical capabilities with a digitally powered patient experience. Its comprehensive, multidisciplinary suite of mental health services includes psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. LifeStance clinicians treat a broad spectrum of mental health conditions, such as anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. The company also offers transcranial magnetic stimulation (TMS) and ketamine therapies, with telehealth services accounting for over 70% of its appointments.

LifeStance Health Group, Inc. operates across 33 states and has more than 550 centers. As of December 31, 2025, the company employed approximately 8,040 psychiatrists, advanced practice nurses, psychologists, and therapists. Its headquarters are located in Scottsdale, Arizona.

LifeStance Health Group's brand reputation has been affected by both positive developments and controversies. The company published clinical outcomes data on April 9, 2026, validating the benefit of mental health treatment at scale. However, LifeStance has faced several lawsuits and reports that have impacted its reputation, including a settlement from shareholders who alleged that LifeStance misled investors about clinician retention rates, a report from Hindenburg Research claiming issues with clinician retention, a class-action lawsuit alleging that the company shared patients' personal information with Meta Platforms Inc. without consent, and lawsuits from former employees for alleged labor violations.

LifeStance Health Group, Inc. is predominantly owned by institutional investors, who collectively held approximately 92.4% of outstanding shares as of December 2025. Major institutional owners include TPG GP A, LLC, FMR LLC, Summit Partners L.P., BlackRock, Inc., Vanguard Group Inc, Silversmith Partners I GP, LLC, Dimensional Fund Advisors Lp, Jennison Associates Llc, UBS Asset Management Americas Inc, and Geode Capital Management, Llc.